Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 21Completed 4Terminated 2Not yet recruiting 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Paclitaxel 83Fulvestrant 64Trastuzumab 62Letrozole 62pembrolizumab 54Carboplatin 51Cyclophosphamide 49pertuzumab 46palbociclib 45Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28olaparib 26Docetaxel 26ribociclib 25abemaciclib 25Specimen Handling 25Epirubicin 20130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × elacestrant × Breast × Clear all
NCT05596409 2026-05-07

ELCIN

Stemline Therapeutics, Inc.

Phase 2 Active not recruiting
61 enrolled
Breast

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

University of Miami

Phase 2 Active not recruiting
24 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡